PT  - JOURNAL ARTICLE
AU  - Mulberry, N.
AU  - Tupper, P.
AU  - Kirwin, E.
AU  - McCabe, C.
AU  - Colijn, C.
TI  - Vaccine Rollout Strategies: The Case for Vaccinating Essential Workers Early
AID  - 10.1101/2021.02.23.21252309
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.23.21252309
4099  - http://medrxiv.org/content/early/2021/02/25/2021.02.23.21252309.short
4100  - http://medrxiv.org/content/early/2021/02/25/2021.02.23.21252309.full
AB  - In planning for upcoming mass vaccinations against COVID-19, many jurisdictions have proposed using primarily age-based rollout strategies, where the oldest are vaccinated first and the youngest last. In the wake of growing evidence that approved vaccines are effective at preventing not only adverse outcomes, but also infection (and hence transmission of SARS-CoV-2), we propose that such age-based rollouts are both less equitable and less effective than strategies that prioritize essential workers. We demonstrate that strategies that target essential workers earlier consistently outperform those that do not, and that prioritizing essential work-ers provides a significant level of indirect protection for older adults. This conclusion holds across numerous outcomes, including cases, hospitalizations, Long COVID, deaths and net monetary benefit, and over a range of possible values for the efficacy of vaccination against infection. Our analysis focuses on regimes where the pandemic continues to be controlled with distancing and other measures as vaccination proceeds, and where the vaccination strategy is expected to last for over the coming 6-8 months — for example British Columbia, Canada. In such a setting with a total population of 5M, vaccinating essential workers sooner is expected to prevent over 200,000 infections, over 600 deaths, and to produce a net monetary benefit of over $500M.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNM, PT, and CC were supported by Natural Science and Engineering Research Council (Canada) Discovery Grants (RGPIN-2019-06911 and RGPIN-2019-06624). CC receives funding from the Federal Government of Canada's Canada 150 Research Chair program and from Genome BC (COV-142). CM and EK were supported by an Alberta Health Partnership grant. No author received payment or services from any third party for any aspect of this work. Funders had no role in the study design, preparation or analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on a GitHub repository. https://github.com/nmulberry/essential-workers-vaccine/